CHChristopher A. Hinckley

Christopher A. Hinckley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher A. Hinckley has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander Barre

    Biogen, Cambridge, Massachusetts (C.A.H., H.N.); Charles River Laboratories Cleveland, Inc., Cleveland, Ohio (Y.K.); Neuroservice, Aix-en-Provence, France (A.S., A.B., B.B.); and Department of Comparative Medicine, Yale University, New Haven, Connecticut (M.H.)

    1 shared publication
  • Alissende Sers

    Biogen, Cambridge, Massachusetts (C.A.H., H.N.); Charles River Laboratories Cleveland, Inc., Cleveland, Ohio (Y.K.); Neuroservice, Aix-en-Provence, France (A.S., A.B., B.B.); and Department of Comparative Medicine, Yale University, New Haven, Connecticut (M.H.)

    1 shared publication
  • Bruno Buisson

    Biogen, Cambridge, Massachusetts (C.A.H., H.N.); Charles River Laboratories Cleveland, Inc., Cleveland, Ohio (Y.K.); Neuroservice, Aix-en-Provence, France (A.S., A.B., B.B.); and Department of Comparative Medicine, Yale University, New Haven, Connecticut (M.H.)

    1 shared publication
  • Christopher D. Whelan

    Biogen Cambridge Massachusetts USA

    1 shared publication
  • Cynthia Gubbels

    Biogen Cambridge Massachusetts USA

    1 shared publication
  • Davide Gianni

    Biogen, Cambridge, USA

    1 shared publication

Latest Publications

  • Open Access

    Detecting MUNC18-1 related presynaptic dysfunction and rescue in human iPSC-derived neurons

    by Manzhao Long, Nicholas B. Gallo, Jennifer Zoll, Sharanya Unnikrishnan, Edward Guilmette, Davide Gianni, Sijia Wu, Christopher A. Hinckley

    Human induced pluripotent stem cell (hiPSC) derived neurons are powerful tools to model disease biology in the drug development space. Here we leveraged a spectrum of neurophysiological tools to characterize iPSC-derived NGN2 neurons. Specifically, we applied these technologies to detect phenotypes associated with presynaptic dysfunction and rescue in NGN2 neurons lacking a synaptic vesicle associated protein MUNC18-1, encoded by syntaxin binding protein 1 gene (STXBP1). STXBP1 homozygous knock out NGN2 neurons lacked miniature post synaptic currents and demonstrated disrupted network bursting as assayed with multielectrode array and calcium imaging. Furthermore, knock out neurons released less glutamate into culture media, consistent with a presynaptic deficit. These synaptic phenotypes were rescued by reconstitution of STXBP1 protein by AAV transduction in a dose-dependent manner. Our results identify a complementary suite of physiological methods suitable to examine the modulation of synaptic transmission in human neurons.


  • Functional evaluation of epilepsy‐associated KCNT1 variants in multiple cellular systems reveals a predominant gain of function impact on channel properties

    by Christopher A. Hinckley, Zhonghua Zhu, Jen‐Hwa Chu, Cynthia Gubbels, Timm Danker, Jonathan J. Cherry, Christopher D. Whelan, Sandra J. Engle, Viet Nguyen

    Objective: Gain of function variants in the sodium‐activated potassium channel KCNT1 have been associated with pediatric epilepsy disorders. Here, we systematically examine a spectrum of KCNT1 variants and establish their impact on channel function in multiple cellular systems.Methods: KCNT1 variants identified from published reports and genetic screening of pediatric epilepsy patients were expressed in Xenopus oocytes and HEK cell lines. Variant impact on current magnitude, current–voltage relationships, and sodium ion modulation were examined.Results: We determined basic properties of KCNT1 in Xenopus oocyte and HEK systems, including the role of extra‐ and intracellular sodium in regulating KCNT1 activity. The most common six KCNT1 variants demonstrated strong gain of function (GOF) effects on one or more channel properties. Analysis of 36 total variants identified phenotypic heterogeneity but a strong tendency for pathogenic variants to exert GOF effects on channel properties. By controlling intracellular sodium, we demonstrate that multiple pathogenic KCNT1 variants modulate channel voltage dependence by altering the sensitivity to sodium ions.Significance: This study represents the largest systematic functional examination of KCNT1 variants to date. We both confirm previously reported GOF channel phenotypes and expand the number of variants with in vitro GOF effects. Our data provide further evidence that novel KCNT1 variants identified in epilepsy patients lead to disease through generalizable GOF mechanisms including increases in current magnitude and/or current–voltage relationships.


  • Open Access

    Characterization of Vixotrigine, a Broad-Spectrum Voltage-Gated Sodium Channel Blocker

    by Christopher A Hinckley, Yuri Kuryshev, Alissende Sers, Alexander Barre, Bruno Buisson, Himanshu Naik, Mihaly Hajos

    Voltage-gated sodium channels (Navs) are promising targets for analgesic and antiepileptic therapies. Although specificity between Nav subtypes may be desirable to target specific neural types, such as nociceptors in pain, many broadly acting Nav inhibitors are clinically beneficial in neuropathic pain and epilepsy. Here, we present the first systematic characterization of vixotrigine, a Nav blocker. Using recombinant systems, we find that vixotrigine potency is enhanced in a voltage- and use-dependent manner, consistent with a state-dependent block of Navs. Furthermore, we find that vixotrigine potently inhibits sodium currents produced by both peripheral and central nervous system Nav subtypes, with use-dependent IC50 values between 1.76 and 5.12 μM. Compared with carbamazepine, vixotrigine shows higher potency and more profound state-dependent inhibition but a similar broad spectrum of action distinct from Nav1.7- and Nav1.8-specific blockers. We find that vixotrigine rapidly inhibits Navs and prolongs recovery from the fast-inactivated state. In native rodent dorsal root ganglion sodium channels, we find that vixotrigine shifts steady-state inactivation curves. Based on these results, we conclude that vixotrigine is a broad-spectrum, state-dependent Nav blocker. SIGNIFICANCE STATEMENT Vixotrigine blocks both peripheral and central voltage-gated sodium channel subtypes. Neurophysiological approaches in recombinant systems and sensory neurons suggest this block is state-dependent.